Praying this may be the answer for my husband who was just told 2 days ago that there's nothing to do, since his marrow isn't working after his 4th Xofigo treatment (see earlier posts below)!!
medpagetoday.com/reading-ro...
Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis: A Case Report
ASCO Publications Corner
01.02.2020 ASCO Reading Room
Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies
ASCO Education Book
12.19.2019 ASCO Reading Room
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Journal of Clinical Oncology
12.06.2019 ASCO Reading Room
Performance Status, Survival, and End-of-Life Care in Adults with Non-Small Cell Lung Cancer Treated With Immunotherapy
Journal of Clinical Oncology
share to facebook
share to twitter
share to linkedin
email article
Panagiotis J. Vlachostergios, MD, PhD; Julia T. Geyer, MD; John Miller, MD; Rebecca Kosloff, MD; Himisha Beltran, MD; and Scott T. Tagawa, MD
Journal of Oncology Practice
This Reading Room is a collaboration between MedPage Today® and: Medpage Today
Below is the abstract of the article. The full journal article is available to read for free on MedPage Today - click here or in the link below
Introduction
Myelophthisis is a type of bone marrow failure resulting from infiltration by cancer cells and manifests with peripheral cytopenias. Although rare in metastatic solid tumors, lung, breast and prostate are the most commonly associated primaries. Besides transfusion support, little is known about the efficacy of systemic therapies in such patients. The condition itself may be a barrier to optimal dosing of cytotoxic chemotherapeutics.
Metastatic castration-resistant prostate cancer (CRPC) remains lethal despite recent therapeutic advances. Although a survival benefit led to the U.S. Food and Drug Administration approval of the cell-based cancer immunotherapy sipuleucel-T in patients with asymptomatic CRPC with nonvisceral metastases, all other randomized trials of immunotherapy have been negative to date, and prostate cancer is believed to be a relatively immunologically "silent" tumor with respect to immune checkpoint inhibitors. The anti–programmed death-1 (PD-1) checkpoint inhibitor pembrolizumab was recently approved for unresectable or metastatic solid tumors characterized by high microsatellite instability or mismatch repair (MMR) deficiency, including prostate cancer.
Up to half of patients with metastatic prostate cancer and germline and/or somatic MMR mutations may experience significant responses to PD-1 inhibition; however, more data are still needed. Herein, we describe a patient with MMR-deficient metastatic CRPC with widespread metastases involving the bone marrow causing myelophthisis, who responded to pembrolizumab.
Read the full article
Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis: A Case Report